Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173015 | 1.00 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL17347037 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL2888640 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL14269196 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL13202685 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL13870610 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL14269193 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL14943299 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL18543369 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 | |
| SCHEMBL12894228 | 0.76 | TDP1 (0.47) | TDP1SIGMAR1DPP4EPHX2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008024337-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | TDP1 2499/4885SIGMAR1 4268/4885DPP4 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.